Twitter: Cognetivity Neurosciences Ltd
  • Sleep disorders are highly prevalent and may affect as much as 48 per cent of older adults
  • Cognetivity Neurosciences (CGN) has validated results for its CognICA technology in measuring the impact of changes in sleep patterns on brain health
  • The sleep technology devices market expected to grow from $15 billion in 2021 to more than $67 billion by 2030
  • Cognetivity Neurosciences (CGN) opened trading at C$0.32 per share

Normal sleep is essential for overall brain health and well-being, including cognition and memory formation. However, sleep disorders are highly prevalent and may affect as much as 48 per cent of older adults.

Cognetivity Neurosciences (CGN) has validated results for its CognICA technology in measuring the impact of changes in sleep patterns on brain health.

It has been a costly and cumbersome challenge for scientists to evaluate cognitive function, but tracking cognitive performance in sleep disorders can help identify the appropriate frequency and duration of treatment.

Dr. Sina Habibi, CEO of Cognetivity, stated that this research and development has opened up a significant market – managing sleep patterns, an area of growing concern for individuals and clinicians worldwide.

“When we add this to the expansion of our collaboration with such a fantastic academic partner as Oxford University, it shows our continued ability to deliver cutting edge research that demonstrates new use cases for our technology and its relevance and suitability for next-generation healthcare and consumer wellness.”

The sleep technology devices market expected to grow from $15 billion in 2021 to more than $67 billion by 2030, and growing interest in consumers in tracking sleep and measuring the impact on performance and health.

Cognetivity’s Chief Innovation Officer, Dr Seyed-Mahdi Khaligh-Razavi will be presenting results on recent work on the impact of sleep on brain health at the 10th Congress of Asian Sleep Research (ASRS) on March 31st in Istanbul, Turkey.

Cognetivity is a technology company that is in the business of helping people with cognitive issues.

Cognetivity Neurosciences (CGN) opened trading at C$0.32 per share.

More From The Market Online

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.

From robotic limbs to new highs, NVIDIA stock is on a roll

NVIDIA Corp. (NDAQ:NVDA; NEO:NVDA) opened Tuesday trading on a positive note, showing a significant upward trend.

Eric Sprott reduces exposure to TRU Precious Metals

Billionaire investor Eric Sprott allows 9 million warrants for shares of TRU Precious Metals (TSXV:TRU) to expire unexercised.